In the past years, we have learnt that tumors co-evolve with their microenvironment, and that
the active interaction between cancer cells and stromal cells plays a pivotal role in cancer …

Age and DNA repair deficiencies are strong risk factors for developing cancer. This is
reflected in the comorbidity of cancer with premature aging diseases associated with DNA …

Colorectal cancer (CRC) is one of the leading cause of cancer death worldwide. Currently,
no effective early diagnostic biomarkers are available for colorectal carcinoma. Therefore …

There is an urgent need for novel diagnostic and therapeutic strategies for patients with
Glioblastoma multiforme (GBM). Previous studies have shown that BCL2 like 13 (BCL2L13) …

Introduction: The standard treatment for locally advanced rectal cancer (LARC) is
neoadjuvant chemoradiotherapy (nCRT). To select patients who would benefit the most from …

Background It is uncertain which biological features underpin the response of rectal cancer
(RC) to radiotherapy. No biomarker is currently in clinical use to select patients for treatment …

Ovarian cancer is one of the most malignant tumors of the female reproductive system, with
high invasiveness. The disease is a severe threat to women's health. The ITGA2 gene …

Over the past few years, multiple immune checkpoint blockers (ICBs) have achieved
unprecedented clinical success and have been approved by regulatory agencies for the …

Glioblastoma (GBM) is the most common aggressive central nervous system cancer. GBM
has a high mortality rate, with a median survival time of 12–15 months after diagnosis. A …

Abstract BCL2L13 is a BCL2-like protein. It has been discovered for two decades, now on
the way to be a hotspot of research with its physiological and pathological meanings found …